CA3097403C - Inhibiteurs de stat3 - Google Patents

Inhibiteurs de stat3

Info

Publication number
CA3097403C
CA3097403C CA3097403A CA3097403A CA3097403C CA 3097403 C CA3097403 C CA 3097403C CA 3097403 A CA3097403 A CA 3097403A CA 3097403 A CA3097403 A CA 3097403A CA 3097403 C CA3097403 C CA 3097403C
Authority
CA
Canada
Prior art keywords
compound
cancer
nrbrc
alkyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3097403A
Other languages
English (en)
Other versions
CA3097403A1 (fr
Inventor
Sofia De Achaval Wied
William E. Bauta
Jr. Cantrell William R.
David John Tweardy
Original Assignee
Baylor College of Medicine
Tvardi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, Tvardi Therapeutics Inc filed Critical Baylor College of Medicine
Priority claimed from PCT/US2019/028135 external-priority patent/WO2019204614A1/fr
Publication of CA3097403A1 publication Critical patent/CA3097403A1/fr
Application granted granted Critical
Publication of CA3097403C publication Critical patent/CA3097403C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

Il est décrit des composés utiles en tant qu’inhibiteurs de STAT3. Il est décrit une composition pharmaceutique contenant ces inhibiteurs, des méthodes de préparation de ceux-ci, ainsi qu’une méthode de traitement ou de prévention de pathologies telles qu’un cancer, une inflammation chronique et une fibrose, à l’aide de ceux-ci.
CA3097403A 2018-04-19 2019-04-18 Inhibiteurs de stat3 Active CA3097403C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862659872P 2018-04-19 2018-04-19
US62/659,872 2018-04-19
US201962793491P 2019-01-17 2019-01-17
US62/793,491 2019-01-17
PCT/US2019/028135 WO2019204614A1 (fr) 2018-04-19 2019-04-18 Inhibiteurs de stat3

Publications (2)

Publication Number Publication Date
CA3097403A1 CA3097403A1 (fr) 2019-10-24
CA3097403C true CA3097403C (fr) 2025-07-08

Family

ID=

Similar Documents

Publication Publication Date Title
EP3773537B1 (fr) Inhibiteurs de stat3
US11026905B2 (en) STAT3 inhibitors
JP6968823B2 (ja) Ｅｇｆｒの分解のための二官能性分子、及び使用方法
EP3398948A2 (fr) Dérivés de ptéridine 2,4,6,7-tétrasubstituée et leurs procédés de synthèse et d'utilisation
EP2010536B1 (fr) Imidazo [1, 2-b]pyridazines, leurs procedes de preparation et leur utilisation en tant que ligands du recepteur gaba
US20200308165A1 (en) Compounds as Ras Inhibitors and Use Thereof
RU2765718C1 (ru) Замещенное производное дигидропирролопиразола
WO2019204427A1 (fr) Procédés de mesure et de stabilisation d'inhibiteurs de stat3
JP2023520595A (ja) ピラゾロピリダジノン化合物、その医薬組成物及びその用途
WO2022005961A1 (fr) Inhibiteurs de prpk
CA3097403C (fr) Inhibiteurs de stat3
HK40073672A (en) Stat3 inhibitors
HK40038526B (en) Stat3 inhibitors
HK40038526A (en) Stat3 inhibitors
CA2992674A1 (fr) Procede de traitement de cancer avec une combinaison de derives de benzylideneguanidine et d'agent chimiotherapeutique
US20250270198A1 (en) Pyridone compounds as trpa1 inhibitors
EA043779B1 (ru) Ингибиторы stat3
US7943611B2 (en) Imidazo[1,2-A]pyridin-3-yl-acetic acid hydrazides, processes, for their preparation and pharmaceutical uses thereof
TW593297B (en) LFA-1 antagonists